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ABSTRACT
HIV-1 is typically CCR5 using (R5) and T cell tropic (T-tropic), targeting memory CD4 T cells throughout acute and chronic
infections. However, viruses can expand into alternative cells types. Macrophage-tropic (M-tropic) HIV-1 variants have evolved
to infect macrophages, which have only low levels of surface CD4. Most M-tropic variants have been isolated from the central
nervous system during late-stage chronic infection. We used the HIV-1 env genes of well-defined, subject-matched M-tropic and
T-tropic viruses to characterize the phenotypic features of the M-tropic Env protein. We found that, compared to T-tropic vi-
ruses, M-tropic viruses infect monocyte-derived macrophages (MDMs) on average 28-fold more efficiently, use low-density CD4
more efficiently, have increased sensitivity to soluble CD4 (sCD4), and show trends toward sensitivity to some CD4 binding site
antibodies but no difference in sensitivity to antibodies targeting the CD4-bound conformation. M-tropic viruses also displayed
a trend toward resistance to neutralization by monoclonal antibodies targeting the V1/V2 region of Env, suggesting subtle
changes in Env protein conformation. The paired M- and T-tropic viruses did not differ in autologous serum neutralization,
temperature sensitivity, entry kinetics, intrinsic infectivity, or Env protein incorporation. We also examined viruses with mod-
estly increased CD4 usage. These variants have significant sensitivity to sCD4 and may represent evolutionary intermediates.
CD4 usage is strongly correlated with infectivity of MDMs over a wide range of CD4 entry phenotypes. These data suggest that
emergence of M-tropic HIV-1 includes multiple steps in which a phenotype of increased sensitivity to sCD4 and enhanced CD4
usage accompany subtle changes in Env conformation.
IMPORTANCE
HIV-1 typically replicates in CD4 T cells. However, HIV-1 can evolve to infect macrophages, especially within the brain. Under-
standing how CCR5-using macrophage-tropic viruses evolve and differ from CCR5-using T cell-tropic viruses may provide in-
sights into viral evolution and pathogenesis within the central nervous system. We characterized the HIV-1 env viral entry gene
from subject-matched macrophage-tropic and T cell-tropic viruses to identify entry features of macrophage-tropic viruses. We
observed several differences between T cell-tropic and macrophage-tropic Env proteins, including functional differences with
host CD4 receptor engagement and possible changes in the CD4 binding site and V1/V2 region. We also identified viruses with
phenotypes between that of “true” macrophage-tropic and T cell-tropic viruses, which may represent evolutionary intermediates
in a multistep process to macrophage tropism.
HIV-1 host cell entry is determined solely by the virion surfaceprotein Env. The Env protein precursor gp160 is cleaved into
two proteins: the external gp120 protein and the membrane-span-
ning gp41 protein, which remain associated as a heterodimer and
form trimers of these heterodimers. Attachment of gp120 to the
host CD4 receptor induces conformational changes in gp120 that
allow a secondary interaction with the host CCR5 coreceptor.
CCR5 binding induces conformational changes in gp41, which
promotes fusion of the viral and cellular membranes. Because the
Env protein is the sole determinant of target cell entry specificity,
any change in the cell types targeted must reflect a change in the
properties of this protein.
The vast majority of HIV-1 isolates sampled during acute and
chronic infections are CCR5-using T cell-tropic (R5 T-tropic) vi-
ruses, which are adapted to (1–3), and replicating in (4–6), CD4
memory T cells. R5 T-tropic viruses require the high densities of
the CD4 receptor found on CD4 T cells for efficient entry and use
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the CCR5 coreceptor, which is most abundant on the memory
subset of CD4 T cells. In approximately one-half of late-stage
HIV-1 infections, a viral population evolves the ability to use
CXCR4 as a coreceptor (7–9). These CXCR4-using T cell-tropic
(X4 T-tropic) viruses use CXCR4 to target CD4 naive T cells (10,
11), which express lower densities of CCR5 and higher densities of
CXCR4 than do CD4 memory T cells (12, 13). Alternatively,
viral populations can evolve to use lower densities of the CD4
receptor, enabling more-efficient entry into macrophages, which
express CD4 at densities 20-fold less than is found on CD4 mem-
ory T cells but express similar levels of the CCR5 coreceptor (14).
Other studies have also observed that macrophages express lower
levels of CD4 than CD4 T cells (13, 15). Most M-tropic variants
use the CCR5 coreceptor (R5 M-tropic), but X4 M-tropic viruses
have been reported (16). Because M-tropic variants are detected
so rarely (3, 17), the true frequency and characteristics of M-tropic
viruses are only beginning to be explored.
Historically, M-tropic variants have been identified by detect-
ing infection of monocyte-derived macrophages (MDMs) in cell
culture. However, different preparations of MDMs can vary
widely in their capacity to be infected—varying both between dif-
ferent donors and from the same donor at different times (13, 14).
Because MDMs have a lower surface density of CD4 than CD4 T
cells, which is a significant impediment to entry by T-tropic vi-
ruses (14, 18, 19), it has been possible to use entry efficiency as a
function of CD4 density to identify viruses that have adapted to
entering macrophages. Initially, this was done using cells engi-
neered to have either high or low levels of CD4 (20). The depen-
dence on receptor level for viral entry can now be demonstrated
most convincingly using the Affinofile cell line, in which the sur-
face density of CD4 and/or CCR5 can be experimentally manipu-
lated (21). Using this approach, it has been possible to identify
M-tropic viruses, most often isolated from the cerebrospinal fluid
(CSF) of subjects late in disease, by their ability to efficiently enter
cells with low CD4 densities (CD4low cells) as a surrogate marker
for macrophage tropism (14, 22). Although it is possible to ob-
serve differences in entry phenotype using MDMs, it is difficult to
account for the inherent variability among both the viruses and
the cells in unequivocally assigning cellular tropism. Differences
in how macrophage tropism is defined can lead to substantially
different observations about M-tropic viruses. Although it is
widely observed that M-tropic viruses are able to enter more effi-
ciently at low CD4 densities (14, 19, 22–26) and are more sensitive
to neutralization by soluble CD4 (sCD4) (27–29) than T-tropic
viruses, few other characteristics are widely agreed upon. Simi-
larly, several amino acid changes in the HIV-1 Env protein have
been associated with macrophage tropism (24, 25, 27, 30–39), but
the changes are not consistent across different subjects when mac-
rophage tropism is defined as a distinct set of evolutionary vari-
ants within that subject (40). Furthermore, viruses isolated from
the brain are sometimes referred to as neurotropic but without a
clear definition of what this means phenotypically other than be-
ing located in the central nervous system (CNS) at the time of
isolation.
In this study, we sought to gain insight into the mechanisms
and consequences of evolving macrophage tropism by investigat-
ing characteristics that are unique to M-tropic and T-tropic vi-
ruses. We generated pseudotyped viruses using HIV-1 env clones
from rigorously defined M-tropic viruses and subject-matched R5
(and in one case X4) T-tropic viruses, which reduced the effect of
natural variation observed in viruses between subjects and al-
lowed us to evaluate the phenotypic consequences specific to the
evolution of macrophage tropism. We first sought to clarify the
magnitude of improved entry efficiency of M-tropic variants for
MDMs by pooling data from a panel of MDM donors infected by
our virus pairs. Next, we carried out neutralization assays using
reagents that target the CD4 binding site (CD4bs) to evaluate the
accessibility of epitopes within the CD4bs after the evolution of
macrophage tropism. To evaluate the hypothesis that M-tropic
Env proteins adopt an “open” conformation (similar to viruses
adapted to tissue culture) to enhance the interaction with CD4, we
examined the overall stability of the Env protein at different tem-
peratures and the ability of neutralizing antibodies to access
epitopes that are normally hidden on primary isolates. We also
tested Env proteins for neutralization by autologous sera to reveal
differential contributions of the antibody-mediated immune
pressure to the evolution of macrophage tropism in the CNS com-
pared to T cell tropism in the blood. We assessed the relative
incorporation of Env protein into the virus particle as a potential
mechanism for increasing interactions with target cell CD4 mol-
ecules. Finally, we used a large panel of subject-matched pairs of
Env-pseudotyped viruses with a range of CD4 usage phenotypes
to evaluate CD4 usage as a predictor of MDM infection. By com-
paring CD4 usage and MDM infectivity, we identified a subset of
viruses with an intermediate entry phenotype that have increased
sensitivity to sCD4 and may represent an evolutionary intermedi-
ate on the way to evolving the full macrophage tropism pheno-
type. Collectively, this work provides new information about the
nature of HIV-1 Env proteins that have evolved to become mac-
rophage tropic.
MATERIALS AND METHODS
Cells. 293T cells and TZM-bl cells (41) were maintained in Dulbecco’s
modified Eagle medium (DMEM) with 4.5 g/liter glucose (Cellgro) sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and
100 g/ml streptomycin (Sigma). Affinofile cells (21) were maintained in
DMEM with 4.5 g/liter glucose (Cellgro) supplemented with 10% dia-
lyzed fetal bovine serum (dFBS) and 50 mg/ml blasticidin (Invitrogen).
Affinofile cells can be induced to express a range of CD4 densities on the
cell surface that at maximum induction is similar to CD4 densities on
TZM-bl cells (E. N. Dukhovlinova and K. T. Arrildt, unpublished data)
and approaches but is still lower than that on CD4 T cells (14).
Monocyte-derived macrophages were prepared as previously de-
scribed (14). Briefly, blood was collected from four healthy donors. Buffy
coats were prepared from whole blood by centrifugation into a Ficoll
gradient (Ficoll-Paque Plus; GE Healthcare). Monocytes were isolated
from the buffy coats by negative selection (EasySep human enrichment kit
without CD16 depletion; StemCell Technologies). Purified monocytes
were maintained in RPMI 1640 medium (Cellgro) supplemented with
10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin (Sigma), and 10
ng/ml recombinant human macrophage colony-stimulating factor (M-
CSF; Gibco).
Study subjects and sources of env gene clones. We examined env gene
clones generated in several studies, including previously described clones
generated from the blood and CSF of five adult subjects infected with
HIV-1 subtype B and diagnosed with HIV-associated neurological disease
(22) and from four pediatric subjects infected with HIV-1 subtype C and
diagnosed with delays in neurological development (42). We also exam-
ined new env clones that were generated from the blood and subject-
matched CSF, semen, or cervicovaginal fluid (CVF) of five subjects in-
fected with HIV-1 subtype B or C (Table 1). In all cases, env gene
amplicons were generated from virion RNA by synthesizing cDNA and
using endpoint dilution PCR. Selected amplicons were cloned into an
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expression vector (pcDNA3.1), and the env clones were used in a trans-
fection procedure to generate pseudotyped viruses.
Generation of pseudotyped viruses. 293T cells were plated at a den-
sity of 2.5  106 cells in a 100-mm dish and incubated at 37°C. After 18 to
20 h, the 293T cells were transfected with 2 g of an env expression vector,
5 g of pNL4-3.LucR-E- plasmid (obtained through the NIH AIDS Re-
search and Reference Reagent Program, Division of AIDS, NIAID, NIH),
and 30 l FuGENE 6 (Promega) in serum-free DMEM. After 5 h, the
medium was fully changed. After 48 h, the supernatant was collected,
filtered through a 0.45-m syringe filter (Millipore), and stored at 80°C
in small, single-use aliquots. Virus stocks were not subjected to multiple
freeze-thaw cycles.
The titers of virus stocks were determined on Affinofile cells induced
to maximum expression of CD4 and CCR5. Infectivity was measured
using a luciferase assay system kit (Promega) and a luminometer (Veri-
tas), which measures in relative light units (RLU). Titration curves within
the linear range of a virus dilution series were used to calculate the volume
of viral stock resulting in 800,000 RLU, which is near the upper limit of the
linear range, for each individual virus. This virus-specific titration volume
was used for infection of MDMs and Affinofile cells. Alternatively, the
volume of viral stock resulting in 150,000 RLU was used for infection of
TZM-bl cells in neutralization assays (43). The p24-Gag concentration of
viral stocks was determined using the p24 AlphaLISA assay (Perkin-
Elmer).
MDM assay. Monocyte-derived macrophages were plated at a density
of 5.0  104 cells per well of a 48-well plate. Five days after plating, a 50%
medium change was made. After an additional 2 days, viruses were added
to the well and the plates were centrifuged at 2,000 rpm for 2 h at 37°C.
The plates were washed once with phosphate-buffered saline (PBS) and
washed once with medium, and then a full medium change was done to
remove unbound virus. After 48 h, the cells were washed twice with PBS
and lysed with 50 l of Reporter lysis buffer (Promega), and the lysate was
stored at 80°C. Virus entry was then assessed by thawing the lysates and
quantifying luciferase expression by using a luciferase assay system (Pro-
mega).
Affinofile cell assay. Assays were performed as described previously
(44). Briefly, Affinofile cells were plated at a density of 2.0  104 cells per
well of a 96-well black plate (Costar) that had been pretreated with poly-
L-lysine (75 l of 0.1 g/liter poly-L-lysine in PBS was added to each well,
plates were incubated at 37°C, and then the solution was removed before
adding the cells). After 18 to 20 h, ponasterone A (Invitrogen) was added
to the medium at a final concentration of 5 nM to induce maximum
expression of CCR5, and doxycycline (Sigma) was added to the medium
at 10 different final concentrations ranging from no drug (minimal induc-
tion) to 5 ng/ml (maximum induction) to induce different levels of CD4
expression. After 20 additional hours, the medium with the chemical in-
ducers was replaced with normal medium (i.e., lacking ponasterone A and
doxycycline) and virus was added to the cells. The plates were centrifuged
at 2,000 rpm for 2 h at 37°C and then incubated at 37°C. After 48 h, the
medium was removed, and the cells were washed once with PBS and then
lysed with 50 l of Reporter lysis buffer (Promega). The lysate was stored
at 80°C. Virus entry was then assessed by thawing the lysates and quan-
tifying luciferase expression by using the luciferase assay system for firefly
luciferase (Promega) or the Renilla luciferase assay system (Promega).
Flow cytometry. Monocyte-derived macrophages were plated at a
density of 1.1  106 cells in a 60-mm dish. Affinofile cells were plated at a
density of 1.8  105 cells in a well of a 24-well plate. Cells were harvested
for flow cytometry simultaneously with the infection of identically treated
cells for experiments that incorporate both measurements. Cells were
removed from culture dishes using nonenzymatic methods to avoid dis-
TABLE 1 Source material and characteristics of HIV-1 env genes
Designation Subject ID env clone Tissuea Tropismb Age class Reference or sourcec
4013 T 4013 P9 Blood R5 T Adult 22
4013 M 4013 C7 CSF R5 M Adult 22
4051 T 4051 P25 Blood R5 T Adult 22
4051 M 4051 C3 CSF R5 M Adult 22
4059 T 4059 P26 Blood R5 T Adult 22
4059 M 4059 C19 CSF R5 M Adult 22
5002 T 5002 P10 Blood X4 T Adult 22
5002 M 5002 C1 CSF R5 M Adult 22
7115 T 7115 P6 Blood R5 T Adult 22
7115 M 7115 C21 CSF R5 M Adult 22
27569 T 27569 P-B10 Blood R5 T Adult Joseph and Kincer
27569 M 27569 C-A11 CSF R5 M Adult Joseph and Kincer
30005 T 30005 P-F10 Blood R5 T Adult Joseph and Kincer
30005 M 30005 C-C12 CSF R5 M Adult Joseph and Kincer
S4007 T 4007 P13 Blood R5 T Pediatric 42
S4007 Int. 4007 C02 CSF R5 Int. Pediatric 42
S4013 T 4013 P14 Blood R5 T Pediatric 42
S4013 Int. 4013 C14 CSF R5 Int. Pediatric 42
S4049 T 4049 P23 Blood R5 T Pediatric 42
S4049 Int. 4049 C03 CSF R5 Int. Pediatric 42
S4058 T 4058 P05 Blood R5 T Pediatric 42
S4058 Int. 4058 C12 CSF R5 Int. Pediatric 42
D929 T 929 PD11 Blood R5 T Adult Dukhovlinova
D929 Int. 929 VB7 CVF R5 Int. Adult Dukhovlinova
D1361 T 1361 P6G1 Blood R5 T Adult Dukhovlinova
D1361 Int. 1361 VE9 CVF R5 Int. Adult Dukhovlinova
PC018 T C018 PG11 Blood R5 T Adult Ping
PC018 Int. C018 S1B2 Semen R5 Int. Adult Ping
a CSF, cerebrospinal fluid; CVF, cervicovaginal fluid.
b R5, CCR5 using; X4, CXCR4 using; T, T cell-tropic; M, macrophage-tropic; Int., intermediate.
c Unpublished sources: B. Joseph and L. P. Kincer, unpublished data; E. N. Dukhovlinova, unpublished data; L. Ping, unpublished data.
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ruption of surface molecules. MDMs were removed using Cell Dissocia-
tion Buffer (Gibco), and Affinofile cells were removed using chilled PBS
(CellGro). All cells were stained with Fixable Aqua dead-cell stain (Invit-
rogen) and saturating concentrations of phycoerythrin (PE)-conjugated
anti-human CD4 antibody (clone RPA-T4; BD Biosciences). We used
QuantiBRITE beads (BD Biosciences), which are conjugated with PE, as a
standard to translate mean fluorescence per cell to the number of CD4
antibody binding sites (ABS) per cell. Flow cytometry was performed
using a Cyan flow cytometer (Beckman Coulter) and analyzed using
FlowJo software (version 9.3.1).
Neutralization assays. Neutralization assays using TZM-bl cells have
been previously described (43). Briefly, a neutralizing antibody, heat-in-
activated polyclonal serum, soluble CD4 (sCD4), or T20 was serially di-
luted across a 96-well black plate (Costar). Virus was added at a single
concentration (approximately 150,000 RLU per well) and incubated with
the antibody, serum, or sCD4 for 60 min at 37°C. TZM-bl cells were added
to a density of 1.0  104 cells per well and incubated for 48 h at 37°C. For
the T20 time course, a single inhibitory concentration (50 g/ml) of T20
was added at different times postinfection. The cells were lysed 48 h
postinfection with BriteLite (PerkinElmer), and luciferase activity was
assessed by measuring luminescence (Victor-Wallac luminometer). Al-
ternatively, the cells were washed once with PBS and lysed with 50 l of
Reporter Lysis Buffer (Promega) for firefly luciferase reporter viruses or
Renilla luciferase assay lysis buffer for Renilla luciferase reporter viruses,
and the lysate was stored at 80°C. Virus entry was then assessed by
thawing the lysates and quantifying luciferase expression by using the
luciferase assay system (Promega) for firefly luciferase reporter viruses or
the Renilla luciferase assay system (Promega) for Renilla luciferase re-
porter viruses.
To assay the stability of infectivity at different temperatures, virus was
incubated at 80, 0, 25, 37, 49, or 60°C for 1 h before adding TZM-bl cells
and infecting them as described above. To test the rate of temperature
inactivation as a function of time, viruses were incubated at 49°C for up to
60 min or were incubated at 0°C for up to 53 h before adding TZM-bl cells
and infecting as described above.
Western blotting. To evaluate the relative quantities of Env protein on
the surface of a virion, viruses were made as described above, except that
they were never frozen. After filtering, 8.0 ml of the cell medium was
centrifuged at 20,500  g for 90 min at 4°C to pellet the virus. The super-
natant was removed, and the pellet was resuspended in PBS at 1/50 of the
original volume. To denature and inactivate the resuspended virus, 5
Laemmli buffer (312.5 mM Tris-Cl pH 6.8, 10% SDS, 25% 2-mercapto-
ethanol, 0.01% bromophenol blue, 50% glycerol) was added to a final
concentration of 1 and incubated at 95°C for 10 min.
The denatured virus was diluted 1:5 to detect Env and 1:50 to detect
p24. Using a 4 to 20% polyacrylamide Tris-glycine gel (Invitrogen), the
denatured virus was loaded at seven different volumes from 1 l to 10 l
to create a titration curve. The gels were electrophoresed at 100 V for 2 h
and then transferred to polyvinylidene difluoride (PVDF) membranes by
electrophoresing at 150 mA per gel for 2 h. The PVDF membrane was
blocked in 5% nonfat dry milk (Bio-Rad) in Tris-buffered saline (TBS) for
1 h at ambient temperature. The blocking solution was decanted, and
fresh blocking solution was added. The primary antibody, either a purified
rabbit anti-gp140 IgG (generously provided by Nancy Haigwood, Oregon
National Primate Research Center, Oregon Health and Science Univer-
sity) or a purified rabbit anti-p24 antibody (NIH AIDS Research and
Reference Reagent Program), was added to the blocking solution at a final
dilution of 1:10,000 and incubated 16 h at 4°C. The primary antibody and
blocking solution were decanted. The PVDF was washed three times for
10 min with 0.03% Tween 20 in TBS. Fresh blocking solution with the
secondary antibody, horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (Bio-Rad), at a final dilution of 1:10,000 was added to the
PVDF and incubated at ambient temperature for 1.5 h. The PVDF was
washed six times for 10 min with 0.03% Tween 20 in TBS. The HRP was
detected using the ECL Prime kit (GE Healthcare) and recorded by expo-
sure to film (GE Healthcare) for 10 s, 20 s, 30 s, 60 s, or 5 min. After the film
was developed, it was analyzed using ImageQuant TL (GE Healthcare).
Titration curves were made for each exposure time, and the inference of
relative amount was made within the dynamic range of exposures for
subsequent analyses.
Statistical analyses. All statistical analyses were calculated using Prism
GraphPad software. A four-parameter logistic equation (4PL; also called a
sigmoidal dose-response curve with a variable slope) was used for all non-
linear regression analysis, except for cold sensitivity, which followed an
exponential decay. Log-transformed MDM infectivity values were ana-
lyzed by paired t test. Antibody and heat sensitivity 50% inhibitory con-
centrations (IC50s) and cold sensitivity half-life values were analyzed by
Wilcoxon signed-rank test, and values outside the limit of detection of
each assay were reported at the limit of detection for the purposes of
nonparametric comparison. CD4 usage descriptive statistics and log-
transformed IC50s for sCD4 were analyzed by paired t test, except when
comparing non-subject-matched intermediate viruses to M-tropic vi-
ruses, where the unpaired t test was used.
RESULTS
Identification of macrophage-tropic and paired T cell-tropic
HIV-1 env isolates. We used env gene expression vectors derived
from one macrophage-tropic (M-tropic) and one T cell-tropic
(T-tropic) virus isolated from each of seven subjects (Table 1).
Five of these subject-matched pairs (from subjects 4013, 4051,
4059, 5002, and 7115) were previously described, with the M-
tropic viruses being classified using the following 3-fold definition
(22, 45). First, the viruses were isolated from the cerebrospinal
fluid of subjects who had slow viral load (VL) decay after initiation
of antiretroviral therapy (ART), which implies that the viruses
were being produced from long-lived infected cells (e.g., macro-
phages/microglia) that continued to produce viruses longer after
new infections were blocked by ART, compared to the rapid VL
decay seen in the blood, consistent with virus produced from in-
fected T cells. Second, phylogenetic analysis of the env genes
showed that these CSF viruses were genetically diverse and distinct
from the T-tropic viruses found in the blood of the same subjects
(i.e., compartmentalized), implying that the CSF viruses were rep-
licating actively and independently from the viruses found in the
blood. Third, reporter viruses pseudotyped with these CSF-de-
rived Env proteins were able to infect Affinofile cells expressing
the minimum density of CD4 (CD4low Affinofile cells) more effi-
ciently than reporter viruses with the subject-matched blood-de-
rived T-tropic Env proteins, indicative of viral evolution to infect
cells with a low surface density of CD4, such as macrophages
within the central nervous system (CNS) compartment. We have
shown that infectivity in CD4low Affinofile cells is an assay that can
reliably identify M-tropic HIV-1 (14, 22) and provides a method
amenable to high-throughput screening. Posttherapy initiation
samples were not available for the remaining two subjects (27569
and 30005), and thus their tropism was assessed by phylogenetic
analyses (compartmentalization) and infection of CD4low cells.
Although Env proteins derived from some of these subjects
were previously assessed in separate studies (14, 22), we reana-
lyzed Env-pseudotyped viruses for entry phenotypes over a wide
range of cell surface CD4 densities, which are shown in Fig. 1a
using a semi-log plot to display the data. Consistent with previous
studies, the Env proteins from the M-tropic clones were signifi-
cantly better at mediating infection of cells expressing the lowest
densities of CD4 (P value  0.006). In addition, there are differ-
ences over the entire CD4 usage curves, which also clearly distin-
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guish the CSF-derived M-tropic viruses from the blood plasma-
derived T-tropic viruses. We found a 1.8-fold change in average
Hill slope (P value  0.0001) and a 2.7-fold change in the average
CD4 50% effective concentration (EC50) (P value  0.02), which
indicates that the M-tropic Env proteins are able to mediate entry
with significantly fewer CD4 molecules than their paired T-tropic
Env proteins and confirms that CD4 receptor density is a potent
restriction factor in Env-mediated entry.
Because most of the variation in CD4 usage between viruses is
represented by the ability to enter using the minimum CD4 levels
expressed on Affinofile cells, we can use a simplified “CD4low us-
age” assay in which virus infection of CD4low Affinofiles is nor-
malized to infection of CD4high Affinofiles (14, 22) to enable
screening larger panels of viruses for CD4 usage. To assess the
variation in pseudotyped virus preparations and evaluate the ef-
fects of the env-deficient genome reporter construct, we pseu-
dotyped five subject-matched pairs of env expression plasmids in
triplicate with either an env-deficient subtype B HIV-1 genome
expression plasmid encoding a firefly luciferase reporter (transfec-
tions 1 to 3) or an env-deficient subtype C HIV-1 genome expres-
sion plasmid encoding a Renilla luciferase reporter (transfections
4 to 6) and performed a CD4low usage assay (Fig. 1b). Overall, the
results between transfections and with the different reporter
constructs were similar, with some detectable variation in
CD4low usage when the same env gene was pseudotyped with
the different reporter constructs (i.e., 4013M and 4051M had
somewhat higher CD4low usage values with the subtype C re-
porter construct), which could be due to differences in the
interactions between the Env proteins and the structural pro-
teins in the pseudoviruses or to variation in the Affinofile cells
between experiments (i.e., infection using the subtype B or
subtype C reporter construct). For each reporter construct,
there was very little variation in CD4low usage between trans-
fections of the same env plasmid. This assay emphasizes the
FIG 1 Increased CD4 usage differentiates M-tropic viruses from T-tropic viruses. (a) Paired T-tropic and M-tropic env genes were used to pseudotype luciferase
reporter viruses. These paired viruses were then used to infect Affinofile cells expressing various levels of CD4, and infectivity was measured by the relative light
units (RLU) produced by luciferase. CD4 densities were measured by flow cytometry and reported as the log10 value of antibody binding sites (ABS) per cell.
Infectivity is normalized to infectivity at the maximum induction of CD4 and fitted to a dose-response curve, which represents the CD4 usage of each virus and
can be described using the Hill slopes and EC50s. Viruses expressing T-tropic Env proteins (T) are represented with closed symbols and solid lines. Viruses
expressing M-tropic Env proteins (M) are represented with open symbols and broken lines. Unique color and shape combinations (as specified in the legend
within the figure) identify the subjects from which the env genes were isolated, and these identifiers are maintained for all of the figures. M-tropic Env proteins
effected a 62-fold increase in average entry at the lowest density of CD4 over subject-matched T-tropic Env proteins (tpaired  4.2, df  6, P value  0.006).
M-tropic Env proteins also had enhanced CD4 usage over the entire range of CD4 densities as described by a 2.7-fold-lower EC50 (tpaired  3.1, df  6,
P value  0.02) and a 1.8-fold-lower Hill slope (tpaired  10, df  6, P value  0.0001) compared to subject-matched T-tropic Env proteins. (b) Five pairs
of T-tropic and M-tropic env genes were pseudotyped in triplicate with either a subtype B (top, transfections 1 to 3) or subtype C (bottom, transfections
4 to 6) env-deficient HIV-1 genome containing a firefly (subtype B) or Renilla (subtype C) luciferase reporter gene. The resulting 60 pseudoviruses (10 env
vectors  2 reporter vectors  3 replicates) were used to infect CD4low Affinofiles, and infectivity was reported as a fraction of infectivity on CD4high Affinofiles
(infected concurrently). The average standard deviation (SD) across transfections for viruses pseudotyped with the subtype B construct is 1.1% (a range of
0.012% to 5.5%) and with the subtype C construct is 2.9% (a range of 0.061% to 11%). There were minor differences in the relative infectivity of viruses produced
with the subtype B reporter versus that produced with the subtype C reporter (SD of differences  5.4%), but these differences were not statistically significant
(tpaired  1.4, df  9, P value  0.21).
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substantial difference in the ability of M-tropic viruses to use
low-density CD4 compared with T-tropic viruses and reveals
the high fidelity of the CD4 usage assays.
Macrophage-tropic Env proteins increase the infectivity of
monocyte-derived macrophages 28-fold over that of T cell-
tropic Env proteins. To evaluate the extent to which infectivity of
monocyte-derived macrophages (MDMs) can distinguish
M-tropic viruses from T-tropic viruses, we used this panel of
seven paired pseudotyped viruses to infect MDMs derived from
four donors. Similar to previous reports (14), we found that virus
infectivity varied up to 5-fold across MDM donors (data not
shown). However, by pooling data from multiple donors we were
able to estimate the magnitude of the differential infectivity on
MDMs for these two groups of viruses. When the relative infec-
tivity data were averaged across the four MDM donors and the
seven virus pairs, we observed that the ability of M-tropic viruses
to infect MDMs was 28-fold higher than that of T-tropic viruses (P
value  0.0004; Fig. 2).
Macrophage-tropic Env proteins are potently inhibited by
soluble CD4 and show a trend toward enhanced sensitivity to
CD4 binding site antibodies but are not differentially inhibited
by a small-molecule drug targeting the CD4 binding site. In or-
der to better understand how the M-tropic Env proteins are able
to mediate entry using lower densities of CD4, we performed a
competitive inhibition assay by incubating sCD4 with the pseu-
dotyped viruses prior to infection and then measured the relative
infectivity (normalized to the viruses incubated without sCD4) on
TZM-bl cells (Fig. 3a). The viruses pseudotyped with M-tropic
Env proteins were, on average, 27-fold more sensitive to sCD4
than those pseudotyped with the paired T-tropic Env proteins (P
value  0.002), confirming that there is a statistically significant
difference in how M-tropic Env proteins interact with CD4 com-
pared to T-tropic Env proteins. We then compared the values for
our panel of 14 pseudotyped viruses (7 subject-matched pairs of
M- and T-tropic Env proteins) with our previously published data
on a large panel of acute and chronic infection subtype C Env-
pseudotyped viruses (3). The subtype B T-tropic pseudoviruses
did not differ significantly in their sensitivity to sCD4 relative to
the acute or chronic subtype C pseudoviruses, suggesting that the
T-tropic pseudoviruses display a sensitivity to sCD4 that is typical
of plasma-derived viruses.
The enhanced interaction between M-tropic Env proteins and
CD4 could be due to having a more exposed CD4 binding site
(CD4bs), to an increased affinity for CD4, or to prematurely shift-
ing into the CD4-induced (CD4i) state (a conformational shift
that occurs following CD4 binding and results in the conforma-
tion that can bind the CCR5 coreceptor). If sensitivity to sCD4 is
due to a more exposed CD4bs, then sensitivity to sCD4 would
predict sensitivity to neutralizing antibodies targeting the CD4bs.
To evaluate exposure of the CD4bs, we performed infectivity as-
FIG 2 M-tropic viruses are better adapted than T-tropic viruses to infection of
MDMs. Paired T-tropic and M-tropic pseudotyped reporter viruses were used
to infect monocyte-derived macrophages (MDMs) isolated from four donors.
Infectivity on MDMs was normalized to infectivity on Affinofile cells express-
ing maximum CD4 levels. Normalized infectivity values were averaged across
donors for each virus and plotted. Closed symbols represent T-tropic Env
proteins (T), and open symbols represent M-tropic Env proteins (M) with
links between subject-matched pairs. Colors and symbol shapes identify the
originating subject as detailed in Fig. 1. Comparing the mean infectivities of
T-tropic and M-tropic viruses revealed that M-tropic Env proteins confer a
28-fold increase in the average MDM infectivity over subject-matched
T-tropic Env proteins. Mean values are listed and marked with broken lines.
The log normalized values were compared between T-tropic and M-tropic
infectivities by paired t test (tpaired  7.0, df  6, P value  0.0004).
FIG 3 M-tropic viruses are significantly more sensitive to neutralization by
sCD4 and show trends toward increased sensitivity to some CD4bs-targeting
antibodies compared to paired T-tropic viruses. Pseudotyped reporter viruses
were exposed to various concentrations of sCD4 (a) or an antibody with an
epitope overlapping the CD4 binding site (CD4bs) b12 (b), VRCO1 (c), or
CH31 (d) in a TZM-bl neutralization assay. IC50s were calculated from dose-
response curves and plotted. Dashed lines represent the limits of detection.
IC50s above the limit of detection (LOD) were plotted at the LOD, except for
pairs where both viruses had IC50s that exceeded the LOD, in which case the
symbols were stacked above the LOD line. The same Env-pseudotyped viruses
were used in each panel: a control group of T-tropic acute (A) and chronic (C)
infection viruses (black asterisks) and our panel of matched T-tropic viruses
(closed symbols) and M-tropic viruses (open symbols) from seven subjects.
The data for the acute and chronic subtype C viruses are reproduced from Ping
et al. (3) to allow a comparison to a large data set of typical viral Env proteins.
Viruses expressing M-tropic Env proteins had a statistically significant 27-fold
increase in sensitivity to neutralization by sCD4 over subject-matched
T-tropic Env proteins (statistical analysis performed on log normalized EC50s;
tpaired  5.5, df  6, P value  0.002). M-tropic Env proteins showed trends
toward sensitivity to neutralization by b12 (Wpaired  10, P value  0.1) and
VRC01 (Wpaired  10, P value  0.3) over subject-matched T-tropic Env
proteins that did not reach statistical significance using a Wilcoxon matched-
pair test. No difference in sensitivity to neutralization by CH31 was observed
(Wpaired  3, P value  0.8).
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says in the presence of antibodies targeting the CD4bs, specifically
b12 (46), VRCO1 (47), and CH31 (48) (Fig. 3b to d). We found
that four of the seven M-tropic clones were more sensitive to neu-
tralization by b12 than were the paired T-tropic clones, but the
remaining three pairs were completely resistant, making the over-
all difference between M-tropic and T-tropic neutralization not
statistically different. Similarly, four of seven M-tropic clones
were more sensitive than the paired T-tropic clones to VRC01
(though one pair was reversed), but again the overall differences in
neutralization were not significant. There was no detectable dif-
ference in CH31 neutralization between the two groups. Two ad-
ditional CD4bs antibodies, F105 and CH103, were tested on a
smaller panel of 10 pseudotyped viruses (five pairs: 4013, 4051,
4059, 5002, and 7115), but none of the viruses showed any neu-
tralization at the maximum level of F105 tested (14 g/ml) and all
but one pair of viruses (4051) had IC50s above the 10-g/ml limit
of detection for CH103 (data not shown). The paired viruses that
were susceptible to neutralization by CH103 had similar IC50s
(4051T, 0.14 g/ml; 4051M, 0.16 g/ml). Taken together, there is
a trend toward increased sensitivity to neutralization by some an-
ti-CD4bs antibodies, but this conclusion is limited by sample size,
which is due to the limited number of independent M-tropic vi-
ruses isolated. Larger panels of paired Env proteins will be needed
to definitively determine whether there are changes in the CD4bs
that can be probed by antibody neutralization.
We also probed the CD4bs of these viruses using the inhibitor
BMS-626529 (Table 2), which is thought to interact with a target
overlapping the CD4bs, though there are conflicting reports about
whether BMS-626529 competes with CD4 for binding to the
CD4bs or whether it binds outside the CD4bs and prevents as-
sumption of the CD4i Env protein conformation (49, 50). In gen-
eral, the IC50s were indistinguishable between paired M-tropic
and T-tropic viruses and ranged from 0.34 nM to 4.2 nM, which is
typical for primary isolates. Two exceptions were the 5002T Env
protein, which was highly resistant (IC50  310 nM) and con-
tained the known resistance mutation S375M (50), and the 4013T
Env protein, which was moderately resistant (IC50  42.0 nM)
and had no known resistance mutations. A tight range of IC50s
across Env proteins suggests that the BMS-626529 inhibitor is able
to access and interact similarly with its target in the CD4bs on both
M-tropic and T-tropic Env proteins.
Macrophage-tropic Env proteins do not have enhanced sen-
sitivity to HIV-1-neutralizing antibodies. To evaluate whether
macrophage tropism is associated with changes in Env protein
conformation in regions outside the CD4bs, we tested the neutral-
ization sensitivity of our well-defined panel of 14 pseudotyped
viruses against a large panel of neutralizing HIV-1 antibodies. We
used five polyclonal sera and HIV-Ig to detect gross changes in
Env protein conformation (Fig. 4a and b) and six monoclonal
antibodies (MAbs) to examine changes in specific epitopes in the
V1/V2 region (Fig. 4c to e), the N-linked glycosylation coat (Fig.
4f), or the membrane-proximal external region of gp41 (MPER;
Fig. 4g to h). There were no significant differences in sensitivity
between the M-tropic and T-tropic Env proteins to any of the
polyclonal antibodies (Fig. 4a and b), implying that there are no
significant changes in neutralization sensitivity as a whole. How-
ever, analysis of the sensitivity to MAbs again suggested possible
differences.
The epitopes of the PG9 and PG16 antibodies (51) are in the
V1/V2 region of HIV-1 Env protein and require interactions with
the N-linked glycosylation sites at amino acids 156 and 160 (52).
Loss of glycosylation at either of these sites confers resistance to
neutralization by PG9 and PG16. Within our panel of seven paired
Env proteins, only one (4013M) has a known resistance mutation
(N160Y), and this Env protein was resistant to all three V1/V2-
antibodies tested. The remaining six M-tropic viruses were almost
uniformly resistant to neutralization by both PG9 and PG16 (Fig.
4c and d), which is in contrast to the paired T-tropic viruses that
showed the wide variation in neutralization sensitivity that was
also observed in the larger panel of acute and chronic infection
Env proteins. This pattern of neutralization resistance in M-tropic
viruses and variable neutralization in T-tropic viruses was contin-
ued in the analysis of V1/V2 antibody CH01 (Fig. 4e), which has a
more complex and conformation-dependent epitope (53). How-
ever, due to the high variation in the control groups and the small
sample size, we were unable to show a statistically significant dif-
ference in neutralization between M-tropic and T-tropic viruses.
These data suggest that the conformation of Env that defines the
surface epitopes, perhaps through the orientation of the carbohy-
drate side chains, may be altered as part of the evolution to be able
to enter cells with a low density of CD4.
The epitope of 2G12 is dependent on glycans at amino acid
positions 295, 332, and 392 with some interactions with glycans at
386 and 448 (54). In our panel of seven pairs, four of the seven
pairs (eight viruses) were resistant to neutralization by 2G12 (Fig.
4f), which is partially explained by loss of glycosylation sites in
seven of eight viruses. The remaining three pairs showed a pattern
of increased sensitivity in the M-tropic viruses compared to the
paired T-tropic viruses. However, the small sample size com-
pounded by resistance mutations that obscured comparisons of
four of seven pairs again limited our ability to assign statistical
significance to this observation. In contrast, antibodies targeting
the MPER showed no difference in neutralization between M-
tropic and T-tropic viruses either in directionality or variability
(Fig. 4g to h). The sensitivity of M-tropic and T-tropic viruses to
2F5 and 4E10 (55) covered similar ranges and contained similar
variance, which does not seem to be correlated by subject or cel-
lular tropism.
Primary isolates from the blood are typically resistant to anti-
bodies targeting the CD4-induced epitopes on the Env protein.
However, most M-tropic viruses were isolated from the relatively
immune-privileged CNS, which may release these viruses from
the selective pressure that is thought to restrict exposure of CD4i
epitopes. In an effort to probe the exposure of CD4i epitopes, we
used two additional MAbs directed at regions of the Env protein
that interact with the coreceptor and are exposed after CD4 bind-
ing. Specifically, we examined MAbs 17b (56), which has an
epitope overlapping the CCR5 binding domain, and 447-52D
(57), which targets the Env protein V3 loop (Fig. 4i to j). Viruses
TABLE 2 Env sensitivity to BMS-626529
Subject ID
IC50 for BMS-626529 (nM)
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pseudotyped with either the M-tropic or T-tropic Env proteins
were highly resistant to both 17b and 447-52D with IC50s near or
above the detection threshold (20 g/ml). Only one virus,
27569 M, showed substantial neutralization sensitivity to 17b or
447-52D, and it was also the virus most sensitive to neutralization
by polyclonal antibodies.
Resistance to CD4i antibodies could reflect that M-tropic vi-
ruses, like most primary isolates, do not expose CD4i epitopes, or
it could reflect an absence of the specific antibody epitopes used to
probe these conformations, which could mask any potential ex-
posure of CD4i epitopes. To determine whether these Env pro-
teins contain epitopes recognizable by the b12, 17b, and 447-52D
antibodies, we have carried out a preliminary analysis by inserting
single-point mutations to encode alanine at position 155 or 177 in
the V1/V2 loop, which is physically distal from the targeted
epitopes. These mutations individually induce an open conforma-
tion in the Env protein of the JR-CSF isolate as measured by in-
creased sensitivity to b12, 17b, and 447-52D (W. D. Graham and
K. T. Arrildt, unpublished data). Neutralizations assays using the
b12, 17b, and 447-52D antibodies were repeated for viruses pseu-
dotyped with the mutant Env proteins that maintained viability.
We observed that at least one of the Env proteins for four of the
five pairs of Env proteins showed increased sensitivity to either
one or two of the antibodies, indicative of the presence of these
FIG 4 Similar to T-tropic viruses, M-tropic viruses are generally resistant to neutralization by non-CD4bs-targeting antibodies with subtle trends toward
increased resistance to V1/V2-targeting antibodies and decreased resistance to a glycan-targeting antibody. Pseudotyped reporter viruses were exposed to various
concentrations of the following in a TZM-bl neutralization assay: polyclonal sera from five HIV-infected subjects (a); purified polyclonal HIV-Ig (b); anti-V1/V2
MAbs PG9 (c), PG16 (d), and CH01 (e); antiglycosylation MAb 2G12 (f); anti-MPER MAbs 2F5 (g), and 4E10 (h); and anti-CD4i MAbs 17b (i) and 447-52D (j).
The data for the acute and chronic infection subtype C viruses are reproduced from Ping et al. (3) to allow a comparison to a large data set of typical viral Env
proteins. IC50s were calculated from dose-response curves and plotted. Dashed lines represent the limits of detection. IC50s above the limit of detection (LOD)
were plotted at the LOD, except for pairs where both viruses had IC50s that exceeded the LOD, in which case the symbols were stacked above the LOD line. Data
for the same Env-pseudotyped viruses were used in each panel: T-tropic acute (A) and chronic (C) infection viruses (black asterisks; panels b to h only), T-tropic
viruses (T; closed symbols), and M-tropic viruses (M; open symbols). Subject-matched viruses are linked, and the IC50s of T-tropic and M-tropic viruses were
compared using a Wilcoxon matched-pair test. M-tropic and subject-matched T-tropic Env proteins were not significantly different in neutralization by
polyclonal sera (FANOVA  0.8 [where ANOVA is analysis of variance], r
2  0.1, P value  0.6) (a) or HIV-Ig (Wpaired  12, P value  0.5) (b) or by
MPER-targeting MAbs 2F5 (Wpaired  1, P value  1) (g) and 4E10 (Wpaired  2, P value  0.9) (h). M-tropic Env proteins trended toward increased resistance
to neutralization by V1/V2-targeting MAbs PG9 (Wpaired  13, P value  0.1) (c), PG16 (Wpaired  13, P value  0.2) (d), and CH01 (Wpaired  10,
P value  0.1) (e) and increased sensitivity to neutralization by glycosylation-targeting MAb 2G12 (Wpaired  10, P value  0.1) (h) compared to subject-matched
T-tropic Env proteins. Thirteen of the 14 viruses were resistant to neutralization by MAbs 17b (i) and 447-52D (j), which target epitopes typically present only
in the CD4-bound conformation of the viral Env protein from primary isolates (for 17b, Wpaired  1, P value  1; for 447-52D, Wpaired  6, P value  0.3).
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epitopes. Because high neutralization sensitivity to antibodies di-
rected at CD4i epitopes is typically associated with tissue culture-
adapted strains in which the Env protein has adopted an overall
open conformation (2, 17, 58, 59), the lack of sensitivity to these
antibodies is consistent with M-tropic Env proteins that, despite
high sensitivity to sCD4, are not in an open conformation.
Macrophage-tropic Env proteins do not have enhanced sen-
sitivity to autologous serum antibodies. Most viruses currently
identified as being M-tropic were isolated from the relatively im-
mune-privileged CNS, which may have protected these viral pop-
ulations from antibody-mediated selective pressure. The CNS
typically maintains IgG at concentrations far lower than that in the
plasma (approximately 400 times lower) (60), though levels may
increase in subjects with HIV-associated neurocognitive disease
(61–63). To better understand the antibody environment in
which M-tropic viral populations evolve, we tested the sensitivity
of five pairs of viruses to neutralization by autologous serum (Fig.
5) that was contemporaneous with the collection of the viruses.
The neutralization levels of paired T-tropic and M-tropic Env-
pseudotyped viruses by autologous serum were nearly identical
in each case, with no distinguishable differences in the IC50s (P
value  1.0). Furthermore, the IC50s for all viruses fell within
the normal range of sensitivity for primary isolates from
chronic infection, with an average IC50 of 1:100. (serum dilu-
tion) and a range of 1:48 to 1:200 (64–74). These observations
suggest that differences in antibody-mediated immune pres-
sure between anatomical compartments are not a major factor
in the evolution of macrophage tropism.
There are no gross stability differences between M-tropic
Env proteins and paired T-tropic Env proteins. Antibodies can
access only the outer surface of the Env spike and cannot reveal
changes in the core structure or stability of the protein. To assess
whether there were differences in the stability of the Env proteins,
we incubated a smaller panel of 10 (representative) pseudotyped
viruses (5 pairs) at different temperatures to infer the stability of
the Env trimers as measured by the loss of infectivity. We first
incubated each of the viruses for 60 min at six different tempera-
tures (80°C, 0°C, 25°C, 37°C, 49°C, and 68°C) prior to infection
of TZM-bl cells and normalized the data to infectivity after incu-
bation at 25°C (Fig. 6a). Overall, the pseudotyped viruses were
most stable at either 25°C or 37°C and were fully inactivated at
68°C. Although different temperatures produced variable levels of
inactivation for individual viruses, neither sensitivity nor resis-
tance to any temperature was consistently associated with either
M-tropic or T-tropic viruses. Our second assay measured the loss
of infectivity over time at 49°C, which has been previously shown
to result in a moderate rate of virus inactivation (75), to provide a
more quantitative assessment of the level of heat sensitivity for
each Env protein (Fig. 6b). Four of the five pairs showed similar
viral decay curves when the T-tropic and M-tropic viruses were
compared. One pair showed a significant difference in tempera-
ture sensitivity over time, with the M-tropic virus being the most
sensitive virus tested (subject 7115). However, this sensitivity was
not recapitulated for other M-tropic and T-tropic clones gener-
ated from the same subject (data not shown). Finally, we mea-
sured the decay of infectivity of the panel of pseudotyped viruses at
0°C over the course of 53 h (Fig. 6c). Sensitivity to cold was highly
variable between viruses, but neither sensitivity nor resistance to
cold was consistent with cellular tropism. Taken together, these
results show that the ability of M-tropic viruses to enter cells using
a low density of CD4 and the enhanced sensitivity to sCD4 are not
the result of a less stable Env protein.
Env-mediated fusion rates do not differ between macro-
phage-tropic and T cell-tropic Env proteins. We next considered
the possibility that enhanced entry could be due to an enhance-
ment in viral fusion with the cellular membrane, which may com-
pensate for low attachment by making each attachment event
more likely to result in entry (76). T20 is a fusion inhibitor that
mimics the C-terminal heptad repeat (CHR) region of gp41,
which normally binds to the N-terminal heptad repeat (NHR) to
form a six-helix bundle that induces virus-host membrane fusion.
However, when T20 binds the NHR, it stabilizes gp41 in a prefu-
sion conformation and blocks binding by the CHR, effectively
blocking fusion. To determine whether there were any significant
differences in sensitivity to T20 between the five pairs of viruses,
we titrated T20 to find the concentration required to inhibit fu-
sion with TZM-bl cells for each of the 10 pseudotyped viruses (Fig.
7a). We did not detect any consistent differences in T20 sensitivity
between the T-tropic and M-tropic Env proteins. We then used a
fully inhibitory T20 concentration (50 g/ml) to compare the
kinetics of fusion between the two groups of viruses as they be-
came resistant to T20, i.e., the time to formation of the six-helix
bundle and fusion with the target cell (Fig. 7b). There was no
difference in the rate of fusion between any of the pairs, suggesting
that the rate of fusion is not a factor in macrophage tropism.
Increased Env protein incorporation does not explain in-
creased CD4 usage by macrophage-tropic Env-pseudotyped vi-
ruses. A simple way for a virus particle to increase the probability
of interacting with CD4 would be to increase the number of Env
trimers on the surface of the virion. To evaluate whether the M-
FIG 5 M-tropic viruses have not evolved an increased sensitivity to autologous serum. Five paired T-tropic (closed symbols, solid lines) and M-tropic (open
symbols, broken lines) pseudoviruses were exposed to heat-inactivated autologous serum (from the same subject and sampling time as the viruses isolated) in a
TZM-bl neutralization assay. The relative infectivity was analyzed as a function of the reciprocal dilution of the autologous serum. No detectable differences in
sensitivity to autologous serum were detected between paired T-tropic and M-tropic viruses (Wpaired  1.0, P value  1.0). The average IC50 across subjects and
tropism is 1:100, with a range from 1:48 to 1:200 (SD  1:50, standard error of the mean [SEM]  1:16).
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tropic Env proteins had increased expression on the surface of the
virion, we used Western blotting to quantify the ratio of gp120 (to
represent Env) to p24 (to represent the number of virions). We
then calculated the relative ratio of M-tropic Env proteins per
virion as a fold change over the paired T-tropic Env proteins per
virion (Fig. 8a). For these experiments, the estimation of the
amount of each protein was conducted using a dilution series to
work within the dynamic (although nonlinear) range of Western
blot analysis (data not shown). The fold change values did not
significantly differ from 1. Based on these results, we conclude that
differential Env protein incorporation does not explain the en-
hanced CD4 usage observed for the M-tropic pseudotyped vi-
ruses.
Env protein incorporation can be affected by interactions been
Env and structural proteins (reviewed in reference 77). We exam-
ined whether such interactions alter specific infectivity (SI) in our
experimental system, where SI is defined as the infectivity per viral
particle (Fig. 8b). SI was assessed by measuring the infectivity of
pseudoviruses produced from the same 10 pairs of env clones car-
rying either the structural proteins encoded by the env-deficient
HIV-1 subtype B reporter genome or subtype C reporter genome
and using p24 concentration to infer the per virion relative infec-
tivity. There were similar trends within each reporter construct in
that there was an approximately 10-fold range of SI values when
comparing a single reporter construct (subtype B or C) across the
different Env proteins. Also, there was a trend toward a small
increase in infectivity of the M-tropic viruses; however, CD4 den-
sities on CD4high Affinofile cells are not saturating for infection by
T-tropic viruses, making it possible that their SI values are under-
estimated. Also, while the subtype C reporter virus appears to
confer a slight enhancement in SI overall, the two reporter con-
structs cannot be directly compared because the different lucifer-
ase reporter enzymes (firefly versus Renilla) may exhibit different
amounts of luminescence, resulting from the same number of
infection events. Thus, although we see variation between Env
proteins, the variation between different subjects is greater than
between the paired M- and T-tropic Env proteins, indicating that
macrophage tropism, defined by the Env protein, is not achieved
by increasing the per-particle infectivity.
CD4 usage is predictive of MDM infectivity and, along with
sensitivity to sCD4, reveals viruses with intermediate pheno-
types. Using well-characterized, subject-matched M-tropic and
FIG 6 M-tropic viruses do not differ from T-tropic viruses in sensitivity to temperature. The effect of temperature on infectivity was assessed for five pairs of
subject-matched T-tropic (closed symbols, solid lines) and M-tropic (open symbols, broken lines) Env-pseudotyped reporter viruses. (a) Viruses were incubated
at various temperatures for 1 h prior to infecting TZM-bl cells, and the remaining infectivity was normalized to infectivity after incubation at 25°C. Viruses with
M-tropic Env proteins were compared with subject-matched T-tropic Env proteins at five temperatures (80°C, 4°C, 37°C, 49°C and 68°C) but revealed no
significant differences between tropism groups (at 80°C, Wpaired  3, P value  0.8; at 4°C, Wpaired  5, P value  0.6; at 37°C, Wpaired  7, P value 
0.4; at 49°C, Wpaired  1, P value  1; at 68°C, Wpaired  1, P value  1). Viruses were incubated at 49°C (b) or 0°C (c) for various lengths of time prior to
infecting TZM-bl cells. The remaining infectivity was normalized to an untreated aliquot of each virus. M-tropic Env proteins differed in some cases from paired
T-tropic Env proteins, but these differences were not correlated with tropism (panel b, Wpaired  7, P value  0.4; panel c, Wpaired  3, P value  0.8).
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T-tropic env genes, we have demonstrated that MDM infectivity
(when averaged over multiple donors), low CD4 usage, and sen-
sitivity to sCD4 are clear phenotypes that can be used to distin-
guish M-tropic viruses from paired T-tropic viruses. Based on
these defined characteristics, we identified seven additional HIV-1
env genes cloned from compartmentalized virus in the CSF early
after HIV-1 infection of infants (42) or in the genital tract of adults
(E. N. Dukhovlinova and L. Ping, unpublished data) that showed
a modest enhancement of entry on CD4low Affinofile cells (i.e.,
“intermediate” between the values of T-tropic and M-tropic vi-
ruses) and seven subject-matched T-tropic Env proteins isolated
from the blood. Viruses with intermediate CD4 usage phenotypes
are rare and may provide information about the evolution of mac-
rophage tropism. We analyzed the viral entry phenotypes of these
additional seven intermediate pairs using Affinofile cells express-
ing CD4 across the full range of densities. We found that viruses
with an intermediate entry phenotype on CD4low cells also showed
differences in entry phenotype compared to both M-tropic and
T-tropic viruses over the entire range of CD4 densities (Fig. 9a).
When we used our entire 14-pair panel of 28 viruses (14 T-tropic,
7 M-tropic, and 7 intermediate) to infect MDMs, we found that
differences in the ability to use CD4 (as captured by the Hill slope
of the CD4 titration curve) was predictive for infectivity on
MDMs (r2  0.57) (Fig. 9b). This result demonstrates that a sub-
stantial fraction of MDM infectivity can be accounted for by the
ability of the Env protein to use low CD4 densities for entry.
Given that the CD4 entry phenotype appears to be continuous
within the dynamic range that was tested, we asked whether this
was also the case for sCD4 sensitivity. As shown in Fig. 3, M-tropic
Env proteins are significantly more sensitive to sCD4 than the
paired T cell-tropic Env proteins. Using the same approach, we
were also able to show that intermediate Env proteins are signifi-
cantly more sensitive to sCD4 than subject-matched T-tropic Env
proteins
(P value  0.0005) (Fig. 9c). Furthermore, the sCD4 IC50s of the
intermediate viruses were similar to those of the well-character-
ized M-tropic viruses. Taken together, this suggests that evolution
of the M-tropic entry phenotype may be a multistep process
marked by increased sensitivity to sCD4 and enhanced entry at
low CD4 densities.
DISCUSSION
HIV-1 evolution to enter and replicate in macrophages results in
Env proteins that can more efficiently utilize the low densities of
CD4 found on macrophages for viral entry. This ability to use a
low density of CD4 is a key feature that distinguishes M-tropic
viruses from the more typical R5 T-tropic viruses, which require
high densities of CD4 for entry into target T cells. We found that
low-density CD4 usage and sensitivity to soluble CD4 (sCD4) are
distinct criteria for macrophage tropism. Furthermore, CD4 entry
phenotypes are more reproducible than the relative infection of
monocyte-derived macrophages (MDMs). We also found sugges-
tive evidence that the evolution of macrophage tropism includes
multiple stages. Although we observed that the enhanced CD4
usage of all the M-tropic viruses was accompanied by an increased
sensitivity to sCD4, we also observed multiple “intermediate” viral
lineages that had significantly increased sensitivity to sCD4 but, in
some cases, had only a slight increase in the ability to use low CD4
densities. Based on these results, we hypothesize that macrophage
tropism evolves through multiple stages that can be marked by an
increase in sCD4 sensitivity, enhancement of CD4 usage, and
other subtle changes in the Env protein conformation.
In order to make a more accurate assessment of the phenotypic
changes that emerge during the evolution of macrophage tropism,
we designed our analysis to contain three vital attributes. First, we
examined pairs of M-tropic and T-tropic env genes isolated from
the same subjects without ex vivo passaging of their virus. This
minimizes the effect of strain-to-strain variation and focuses our
FIG 7 M-tropic viruses have fusion kinetics similar to those of T-tropic viruses. Inhibition assays with T20 were performed on five pairs of subject-matched
T-tropic (closed symbols, solid lines) and M-tropic (open symbols, broken lines) Env-pseudotyped reporter viruses. (a) Viruses were exposed to different
concentrations of T20 prior to infecting TZM-bl cells, and the remaining infectivity was normalized to untreated virus. T20 dose-response curves did not differ
detectably between matched pairs (Wpaired  9, P value  0.3) and were similar across subjects. (b) A saturating concentration (50 g/ml) of T20 was added to
viruses at various times after the addition of cells. Resistance to T20 over time was plotted as a normalized value of remaining infectivity. The resulting measures
of fusion kinetics did not differ detectably between matched pairs (Wpaired  5, P value  0.6) and were similar across subjects.
Arrildt et al.
11304 jvi.asm.org November 2015 Volume 89 Number 22Journal of Virology
analyses on the evolutionary event(s) that took place within each
subject. Also, because we used a single pair of env genes from each
subject, each comparison was an independent observation. Sec-
ond, we analyzed the phenotypes of Env proteins expressed from
env genes that had been generated by endpoint dilution PCR,
which avoids artificial recombinants during amplification. Third,
we made phenotypic comparisons across a group of env gene pairs
from different subjects to identify generalizable differences be-
tween T-tropic and M-tropic viruses. These key features allowed
us to further define the properties of Env proteins that result in
low-density CD4 usage and an M-tropic phenotype.
Infection of MDMs ex vivo has long been used as a measure of
macrophage tropism (17, 23, 26, 78–81). However, different prep-
arations of MDMs vary in their ability to be infected in ways that
have not been controlled experimentally (13, 14, 80). The typical
approach to this substantial experimental problem has been to
compare several donors and infer a result. An additional compli-
cation of this approach is that R5 T-tropic viruses also vary widely
in their ability to infect MDMs (14). This two-dimensional vari-
ability (virus and cells) makes it difficult to unequivocally assign
cellular tropism in isolation. However, by pooling MDM infection
data from four donors and multiple subject-matched M-tropic
and T-tropic pairs of viruses, we found a 28-fold increase in aver-
age MDM infection by M-tropic over T-tropic viruses (Fig. 2).
These data provide a quantitative estimate of the typical gain in
efficiency of MDM infectivity achieved in transitioning to macro-
phage tropism.
The difference in CD4 density on the surface of macrophages
and CD4 T cells inspired the use of cell lines with either high or
low levels of CD4 as a method to assess the relationship between
efficiency of CD4 usage and macrophage tropism (26, 80, 82, 83).
The efficiency of CD4 usage as a surrogate phenotype for macro-
phage tropism is most easily demonstrated using Affinofile cells,
in which CD4 expression can be varied (21) over a wide range and
can approximate the surface densities of CD4 on T cells and on
MDMs (14). This more-sensitive measure of CD4 usage allowed
us to identify HIV-1 variants that are characterized by both an
intermediate entry phenotype on CD4low cells and an intermedi-
ate entry phenotype on MDMs (Fig. 9b). Based on this analysis, we
were able to demonstrate that HIV-1 infection efficiency on
CD4low cells predicts macrophage tropism and also predicts inter-
mediate entry phenotypes.
We have focused our study on the role of HIV-1 Env in medi-
ating cell entry and so have not considered other potential viral
proteins or sequences that may evolve as part of the adaptation to
macrophages. We have ruled out that the differences observed
between M-tropic and T-tropic viruses result from differences in
the specific infectivity as conferred by their Env proteins (Fig. 8b).
We also evaluated whether increased Env protein incorporation,
which is mediated by interactions between Env and Gag proteins,
could contribute to enhanced CD4 usage but found comparable
levels of Env proteins per viral particle between subject-matched
T-tropic and M-tropic virions (Fig. 8a). Thus, the M-tropic and
T-tropic viruses are equivalent in how they contribute to particle
formation and confer infectivity in the presence of high levels of
CD4, with the differences in viruses being much greater in viruses
isolated between subjects than between the M-tropic and T-tropic
viruses present within a subject.
The enhanced ability of M-tropic viruses to use low CD4 den-
sities for entry suggests an altered interaction between Env and
CD4. This suggestion is supported by the observation that the Hill
slope determined by CD4 titration is significantly different be-
tween these two groups of viruses (Fig. 1a). Previous studies have
reported that M-tropic variants are also more sensitive to sCD4
than T-tropic variants (27–29). We confirmed this observation by
showing that M-tropic variants were on average 27-fold more sen-
sitive to sCD4 than their T-tropic counterparts (Fig. 3a). How-
ever, we found no difference in the ability of M-tropic or T-tropic
viruses to interact with the CD4 binding site (CD4bs) small-mol-
ecule agonist BMS-529626 (Table 2). A previous report found
differences in sensitivity to BMS-663068 (the prodrug form of
BMS-626529) when comparing M-tropic and T-tropic viruses
(84); however, that study included multiple and unequal numbers
of clones from each compartment of several subjects, which com-
plicates the statistical analysis, which assumes independence of
observations. When we probed with a series of CD4bs antibodies,
we found suggestive patterns in two of the three CD4bs antibodies
tested that hinted at an increased sensitivity of M-tropic viruses in
the pairs of viruses that were not completely resistant (Fig. 3b to
FIG 8 M-tropic Env proteins are incorporated at levels similar to those of
T-tropic Env proteins. (a) Western blot analysis was used to evaluate the rel-
ative incorporation of Env proteins into virions using five pairs of T-tropic and
M-tropic Env-pseudotyped viruses. For each virus, the abundance of Env pro-
tein was detected by Western blotting normalized to the abundance of Gag.
The normalized values of Env proteins in M-tropic viruses were compared to
those of subject-matched T-tropic viruses and reported as the fold change
value of M-tropic over T-tropic Env protein incorporation. The fold change
values (mean  1.4, SD  0.8) were not found to deviate significantly from a
hypothetical mean of 1 (tpaired  1, df  4, P value  0.3), which represents the
null hypothesis of an equal abundance of Env proteins on the surface of viruses
expressing T-tropic and M-tropic Env proteins. (b) Five paired T-tropic (T,
closed symbols) and M-tropic (M, open symbols) env genes were pseudotyped
with an env-deficient HIV-1 genome that was either subtype B with a firefly
luciferase reporter gene (SubB) or subtype C with a Renilla luciferase reporter
gene (SubC). Virion density was represented by p24 concentration and the
titers of infectivity were determined on CD4high Affinofile cells. The specific
infectivity (SI) values reported are the linear relationship of infectivity (RLU)
per virion as represented by a structural protein product, p24-Gag (fg). Al-
though the subtype C construct gives overall higher SI values, the effects of
HIV-1 subtypes cannot be directly compared, because different reporters are
used. Despite a small apparent trend of increased SI of M-tropic viruses in both
reporter constructs, any differences in SI between paired T-tropic and M-
tropic viruses are not significant when taken together (Wpaired  13, P value 
0.13) or separated by reporter construct (for SubB, Wpaired  13, P value 
0.13; for SubC, Wpaired  9, P value  0.31). Also, because the CD4 density on
CD4high Affinofiles is saturating for M-tropic viruses and not saturating for
T-tropic viruses, the SI values for T-tropic viruses are likely an underestimate,
which may account for a slight reduction in the observed SI for T-tropic vi-
ruses compared to that for M-tropic viruses.
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d). Two additional CD4bs antibodies, F105 and CH103, are typi-
cally nonneutralizing in primary isolates, which has been sug-
gested to result from steric restriction related to the angle of access
between the antibodies and the Env trimer (85–87). The five pairs
of viruses tested against F105 and CH103 were almost uniformly
resistant to neutralization (data not shown), suggesting that the
angle of CD4 access is not dramatically altered in the M-tropic
viruses. The variability in antibody sensitivity between Env pro-
teins to these antibodies limits the statistical power of these anal-
yses, given the limited number of subject-matched M-tropic and
T-tropic Env pairs available. However, the patterns of increased
sensitivity to the relatively bulky CD4bs antibodies, when coupled
with the significant increases in sensitivity to sCD4, suggest that
conformational differences around the CD4 binding site may exist
in Env proteins from M-tropic viruses.
We also examined whether conformational differences around
the CD4 binding site create a more open conformation. Early
observations revealed that tissue culture-adapted viruses, in the
absence of antibody selection, result in the premature exposure of
CD4-induced epitopes (88–91), indicating that the Env protein
for these viruses is in a more open conformation that exposes the
coreceptor binding site. Furthermore, studies have shown that
tissue culture-adapted viruses evolved to use low CD4 for entry
(92, 93) were more sensitive to sCD4 (94–96) and had greater
sensitivity to antibody neutralization than typical primary isolates
(58, 89, 92, 97). Together, these observations raised the possibility
that these phenotypes covary and are generated by the same mech-
anism. To determine whether selection to use low CD4 densities
for cell entry results in an open Env protein conformation, we
examined Env protein sensitivity to polyclonal sera and MAbs
directed against the V3 and CD4i epitopes as a general probe for
these two conformational states. We found that there was no dif-
ference in antibody sensitivity to polyclonal sera or to most MAbs
when comparing the M-tropic and T-tropic viruses (Fig. 4), indi-
cating that M-tropic viruses have not assumed the open confor-
mation of tissue culture-adapted viruses. Furthermore, there was
no difference in T-tropic and M-tropic viruses in sensitivity to
autologous, contemporaneous serum (Fig. 5), and the IC50s from
all viruses tested were similar to those typically reported for
chronic infection (64–74). However, M-tropic viruses appeared to
be more resistant to the V1/V2-targeted MAb PG9 (Fig. 4c), sug-
gesting that M-tropic viruses may differ in the Env protein con-
formation of the V1/V2 region, which is now understood to be
highly ordered (52, 98) and is thought to contribute to the struc-
ture and function of the Env trimer (99–103). Although our ability
to assign significance to V1/V2 antibody resistance as a feature of
macrophage tropism is limited by sample size (n  7) and the
inherent variability to the neutralization of primary isolates, this
observation is consistent with another obtained using a larger
panel of unpaired T-tropic and M-tropic viruses (29). Overall, the
FIG 9 Viruses of intermediate CD4 usage reveal a correlation between CD4 usage and MDM infectivity. Seven pairs of subject-matched Env-pseudotyped
viruses in which one virus had a modest enhancement in entry of CD4low Affinofile cells (intermediate, Int.) and the other virus was T-tropic (T) were analyzed
and plotted, and the data were overlapped for the original seven pairs of M-tropic (M) and T-tropic (T) viruses shown in Fig. 1. (a) CD4 usage of intermediate
(open symbols, broken lines) and T-tropic (closed symbols, solid lines) viruses was evaluated by the Affinofile cell assay as previously described and plotted
against previously shown data for subject-matched T-tropic (solid light gray lines) and M-tropic (dotted light gray lines) viruses from Fig. 1. Unique colors are
used to identify each subject as specified in the figure legend (the overlap in symbols with those from Fig. 1 is not meaningful). The intermediate viruses differ
from paired T-tropic viruses in Hill slope (tpaired  2.9, df  6, P value  0.03) but not in EC50 (tpaired  1.0, df  6, P value  0.34). Similarly, intermediate
viruses also differ from unpaired M-tropic viruses, but only in EC50 (tpaired  2.5, df  12, P value  0.03) and not Hill slope (tpaired  0.09, df  12, P value 
0.93). (b) CD4 usage was represented by Hill slope values for each virus, which was plotted against log normalized values of infectivity on MDMs. We evaluated
the correlation of CD4 usage and MDM infection and plotted the linear regression (solid line) with the 95% confidence band (broken lines). Variation in CD4
usage could explain 57% of the variation in MDM infectivity (r2  0.57, Sy.x  0.66 [where Sy.x is residual standard deviation], P value  0.0001). (c)
Neutralization sensitivity to sCD4 was evaluated in a TZM-bl neutralization assay as previously described and reported as IC50s. Subject-matched pairs of
intermediate (Int., open symbols) and T-tropic (T, closed symbols) viruses were plotted against data from Fig. 3a for subject-matched pairs of T-tropic (T, closed
symbols) and M-tropic (M, open symbols) viruses and the panel of viruses from acute (A) and chronic (C) infections (black asterisks). The colors and symbols
are the same as those identified in Fig. 1a and 9a. Subject-matched viruses are linked. Similar to M-tropic Env proteins, Int. Env proteins are 23-fold more sensitive
to neutralization by sCD4 than subject-matched T-tropic Env proteins (tpaired  6.8, df  6, P value  0.0005).
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neutralizing antibody sensitivity properties of M-tropic Env pro-
teins reveals them to be more like R5 T-tropic Env proteins than
tissue culture-adapted variants, but with intriguing differences in
the CD4bs and perhaps the V1/V2 loop region.
Dissociation of attached virions prior to successful entry is
common (76) and is likely to be a more substantial problem when
CD4 is at a low density. Increased efficiency of postattachment
entry steps may be able to compensate when attachment condi-
tions are poor, which led us to examine the properties of fusion
(the final step) and the properties that may affect the conforma-
tional changes that occur between attachment and fusion. Differ-
ences in Env protein stability affect the conformational changes
required for entry (104), and differences in stability can be probed
by sensitivity to inactivation at different temperatures. Env pro-
teins display variation in sensitivity to heat (75, 104, 105) and cold
(105–107). Heat lability is a feature of the open conformation of
tissue culture-adapted viruses but not of comparatively stable pri-
mary isolates (75, 104). Although there was some variation in heat
sensitivity between Env proteins from different subjects, the sub-
ject-matched M-tropic and T-tropic virus pairs were generally
indistinguishable (Fig. 6b). There were significant differences in
cold sensitivity within pairs, but sensitivity was inconsistent across
T-tropic or M-tropic Env protein pairs (Fig. 6c). Therefore, ther-
mal sensitivity is also unlikely to be a coevolving feature of HIV-1
cellular tropism or CD4 usage. In contrast, fusion was consistent
within a subject-pair, despite some variation between viruses from
different subjects (Fig. 7). Overall, we found no evidence that fu-
sion efficiency or Env protein instability is linked to cellular tro-
pism or CD4 usage. From these observations, features of macro-
phage tropism appear to be limited to the Env-CD4 interaction.
The evolutionary path to HIV-1 macrophage tropism remains
poorly understood. A number of Env substitutions have been sug-
gested to contribute to macrophage tropism (24, 25, 27, 30–39),
but none of these suggested mutations can distinguish the paired
M-tropic and T-tropic viruses used in our study. By including
additional HIV-1 variants identified by intermediate CD4 usage,
we observed that both MDM infection and low CD4 usage vary
across a wide range. This suggests sequential adaptation to infect-
ing macrophages that may require the accumulation of several
mutations. Direct comparison revealed that variation in CD4 us-
age could explain more than one-half of the observed variation in
MDM infection (Fig. 9b). We do not know if other factors also
impact entry into macrophages or if the remaining variation is due
to experimental variation.
We previously showed that T-tropic and M-tropic viruses dif-
fer in CD4 usage but not in CCR5 usage, as measured by sensitivity
to maraviroc (14). We also observed that M-tropic and interme-
diate variants have similar increases in sensitivity to sCD4 com-
pared to T cell-tropic variants (Fig. 9c). Other groups have also
identified viruses from the CNS that, like our intermediate viruses,
are sensitive to sCD4 but unable to efficiently infect MDMs (for
examples, see references 28 and 108). The lack of a positive rela-
tionship between sensitivity to sCD4 and the ability to infect
MDMs made it difficult for previous studies to assign tropism for
these viruses. The increased sensitivity of our CD4 usage assay
allowed us to detect a group of viruses with intermediate enhance-
ment of CD4 usage, sensitivity to sCD4, and an intermediate abil-
ity to infect MDM in vivo. Together, these findings imply that
sCD4 sensitivity is a phenotype that can be detected early in the
enhancements in low CD4 usage. Also, the general resistance to
neutralizing antibodies combined with a pattern of sensitivity to
sCD4 indicates that M-tropic Env proteins exist in a state that is
distinct from both R5 T cell-tropic Env proteins (which are resis-
tant to sCD4) and tissue culture-adapted Env proteins (which are
globally sensitive to neutralization).
Because our viruses represent a cross-section of viral popula-
tions rather than a longitudinal study of evolving populations, it is
difficult to determine whether a continuous range of values (e.g.,
CD4 usage or MDM infectivity) represents a continuous pheno-
type or a large variation around a bimodal phenotype. However, if
CD4 usage and MDM infectivity are on a multistep evolutionary
path to macrophage tropism (as suggested by our detection of
intermediates), then defining the mutations on this pathway and
understanding the nature of the change in the interaction between
the viral Env protein and the host CD4 receptor remain as impor-
tant questions to inform our understanding of the evolution of
macrophage tropism.
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